Cancer treatment and survivorship statistics, 2022
2022/06/23 by Kimberly D. Miller, Letícia Nogueira, Leticia Nogueira +8 · 42 citations
Economics, Econometrics and Finance · Medicine · #Cancer survivorship and care #Economic and Financial Impacts of Cancer #Global Cancer Incidence and Screening
paper · doi:10.3322/caac.21731
openalex publication_date 2022/06/23 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
Abstract
The number of cancer survivors continues to increase in the United States due to the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries, vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics, and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Database are presented for the most prevalent cancer types by race, and cancer-related and treatment-related side-effects are also briefly described. More than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were alive on January 1, 2022. The 3 most prevalent cancers are prostate (3,523,230), melanoma of the skin (760,640), and colon and rectum (726,450) among males and breast (4,055,770), uterine corpus (891,560), and thyroid (823,800) among females. More than one-half (53%) of survivors were diagnosed within the past 10 years, and two-thirds (67%) were aged 65 years or older. One of the largest racial disparities in treatment is for rectal cancer, for which 41% of Black patients with stage I disease receive proctectomy or proctocolectomy compared to 66% of White patients. Surgical receipt is also substantially lower among Black patients with non-small cell lung cancer, 49% for stages I-II and 16% for stage III versus 55% and 22% for White patients, respectively. These treatment disparities are exacerbated by the fact that Black patients continue to be less likely to be diagnosed with stage I disease than White patients for most cancers, with some of the largest disparities for female breast (53% vs 68%) and endometrial (59% vs 73%). Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based strategies and equitable access to available resources are needed to mitigate disparities for communities of color and optimize care for people with a history of cancer. CA Cancer J Clin. 2022;72:409-436.
Citations
Cited by
- Colorectal cancer statistics, 2023
- Prostate cancer statistics, 2025
- Breast Cancer Statistics, 2022
- Cancer treatment and survivorship statistics, 2025
- Identification of the key DNA damage response genes for predicting immunotherapy and chemotherapy efficacy in lung adenocarcinoma based on bulk, single-cell RNA sequencing, and spatial transcriptomics
- Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review
- Comparative efficacy of psychological interventions on anxiety and depression in patients with cancer: A systematic review and network meta-analysis
- Reproductive Concerns Among Young Adult Women With Breast Cancer: A Systematic Review and Meta‐Analysis
- AACR Cancer Progress Report 2024: Inspiring Science—Fueling Progress—Revolutionizing Care
- Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer
- ZNF554 Inhibits Endometrial Cancer Progression via Regulating RBM5 and Inactivating WNT/β-Catenin Signaling Pathway
- Alterations in Tryptophan Metabolism and the Indole Pathway in Colorectal Cancer Patients: A Systematic Review and Meta‐analysis
- The role of natural language processing in improving cancer care: A scoping review with narrative synthesis
- Reassessing onco-exceptionalism: equity and resource allocation in immunotherapeutic cancer treatments
- Targeting CaMKIIδ overcomes therapy resistance in acute myeloid leukemia by suppressing the STAT3/CDK6/BCL-2 survival axis
- Higher adherence to the EAT-Lancet reference diet is inversely associated with mortality in a UK population of cancer survivors
- CT Radiomics-Based Explainable Machine Learning Model for Accurate Differentiation of Malignant and Benign Endometrial Tumors: A Two-Center Study
- TRPM8 indicates poor prognosis in colorectal cancer patients and its pharmacological targeting reduces tumour growth in mice by inhibiting Wnt/β-catenin signalling. [europepmc]
- Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. [europepmc]
- Melanogenesis and the Targeted Therapy of Melanoma. [europepmc]
- Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. [europepmc]
- Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming? [europepmc]
- Harnessing cancer stem cell-derived exosomes to improve cancer therapy. [europepmc]
- Radioimmunotherapy in colorectal cancer treatment: present and future. [europepmc]
- Colorectal Cancer Organoid-Stroma Biobank Allows Subtype-Specific Assessment of Individualized Therapy Responses. [europepmc]
- A reinforcement learning model for AI-based decision support in skin cancer. [europepmc]
- The First Cold Atmospheric Plasma Phase I Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer. [europepmc]
- Nanoparticles in Medicine: Current Status in Cancer Treatment. [europepmc]
- Integration of single-cell RNA sequencing and bulk RNA transcriptome sequencing reveals a heterogeneous immune landscape and pivotal cell subpopulations associated with colorectal cancer prognosis. [europepmc]
- Recent Studies in Photodynamic Therapy for Cancer Treatment: From Basic Research to Clinical Trials. [europepmc]
- How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology. [europepmc]
- Biomarkers and targeted therapy for cancer stem cells. [europepmc]
- The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles. [europepmc]
- ALYREF-mediated RNA 5-Methylcytosine modification Promotes Hepatocellular Carcinoma Progression Via Stabilizing EGFR mRNA and pSTAT3 activation. [europepmc]
- ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework. [europepmc]
- ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer. [europepmc]
- Developing national cancer survivorship standards to inform quality of care in the United States using a consensus approach. [europepmc]
- Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. [europepmc]
- Prevalence of cancer survivors in the United States. [europepmc]
- CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity. [europepmc]
- Cancer treatment and survivorship statistics, 2025. [europepmc]
- Prostate cancer statistics, 2025. [europepmc]
Related